Headlands Technologies’s VanEck Pharmaceutical ETF PPH Stock Holding History

Headlands Technologies’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-231	Closed	-$21.1K	–	1449
2025 Q1	$21.1K	Buy	+231	New	+$20.8K	﹤0.01%	850
2024 Q3	–	Sell	-44	Closed	-$4.03K	–	1461
2024 Q2	$4.03K	Buy	+44	New	+$3.93K	﹤0.01%	1031

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Headlands Technologies's PPH Position: Q2 2025 in Review

Headlands Technologies sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2025, closing a stake of 231 shares — an estimated $21.1K sold.

Headlands Technologies first reported a position in PPH in Q2 2024 and held it in 2 quarters. The position peaked at $21.1K in Q1 2025. 129 funds tracked by Wall St. Rank hold PPH as of Q2 2025.

Headlands Technologies reported no remaining VanEck Pharmaceutical ETF position as of Q2 2025 after selling out during the quarter.
Headlands Technologies sold 231 VanEck Pharmaceutical ETF shares in Q2 2025, an estimated $21.1K.
Headlands Technologies first reported a position in VanEck Pharmaceutical ETF in Q2 2024 and held it in 2 quarters.
Headlands Technologies's VanEck Pharmaceutical ETF position peaked at $21.1K in Q1 2025.
129 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2025.

Based on Headlands Technologies's 13F filing for Q2 2025, filed 14 Aug 2025.